From Chemistry to Clinic: A Review of Latanoprostene Bunod and Its Therapeutic Potential.

Open-Angle Glaucoma (OAG) is a progressive optic neuropathy and a major cause of irreversible blindness worldwide. Lowering Intraocular Pressure (IOP) remains the most effective approach for slowing disease progression. Latanoprostene bunod (LBN) ophthalmic solution 0.024% (Vyzulta®) is a nitric oxide (NO)-donating prostaglandin analogue developed to enhance aqueous humor drainage through two complementary pathways. Following topical administration, LBN is converted into latanoprost acid and a nitric oxide-releasing metabolite. Latanoprost acid increases uveoscleral outflow, whereas nitric oxide improves conventional outflow by relaxing the trabecular meshwork and Schlemm's canal. Clinical studies have shown that LBN provides significant reductions in IOP in patients with OAG and ocular hypertension. In the phase III APOLLO and LUNAR trials, LBN demonstrated efficacy comparable to, and in some analyses greater than, timolol 0.5%. Long-term data from the JUPITER study further confirmed sustained IOP reduction during 12 months of treatment. LBN is generally well tolerated, with conjunctival hyperemia, mild ocular irritation, and instillation-site discomfort being the most frequently reported adverse events. Beyond its clinical utility, several synthetic approaches have been reported for the preparation of LBN. These include esterification and alkylation strategies involving nitrooxyalkyl derivatives, as well as routes based on bromobutyl intermediates followed by nitrate substitution. Patent literature has further described process improvements aimed at enhancing purity, scalability, and manufacturing efficiency. Overall, current evidence supports LBN as an effective and well-tolerated therapeutic option for patients with OAG or ocular hypertension. Continued improvements in synthetic methodologies may facilitate cost-effective production and broader clinical accessibility.